Infliximab (TNF-alpha) Antibody, Monoclonal

TA-650,cA2

Infliximab is a humanized antibody against tumor necrosis factor ? (TNF-?) that is used in the treatment of Crohn's disease and rheumatoid arthritis.Infliximab is a IgG1? monoclonal antibody that binds to soluble and transmembrane forms of TNF-? with high affinity to disrupt the pro-inflammatory cascade signalling.Binding of the antibody to TNF-? prevents TNF-? from interacting with its receptors.Infliximab does not neutralize TNF-? (lymphotoxin-?),a related cytokine that utilizes the same receptors as TNF-??Label.Blocked actions of TNF-? further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6),reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes),increased levels of nuclear factor-?B inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins?3. Its inhibitory actions on TNF-? was demonstrated in human fibroblasts,endothelial cells, neutrophils, B and Tlymphocytes and epithelial cells?Label.Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-?,infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal?Label.

PBS buffer pH7.5

batch dependent

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Chimeric / TNF-alpha [Homo sapiens]

homo sapiens

>95%

Drug Analogues

CHO cells

Optimal dilutions for each application to be determined by the researcher.